All News
ACR 2025 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
Read Article
ACR25 Best Abstracts - Day 4
Here's the last installment of our "ACR Best" abstracts as chosen by the RheumNow faculty. Most of these were from the final, day 4, but a few were noteworthy holdovers from day 3. Enjoy!
Read Article
Halloween ACR Guidance (10.31.25)
Dr. Jack Cush recaps ACR2025 with suggestions on how to best learn ACR25 content from RheumNow.com and our articles, videos and podcasts.
Read Article
📖➡️The GCA story continues with new data from a Phase 3 trial of a JAKi, sponsored by AbbVie Medical Affairs + Health Impact.
🔥 Hot off the press from ACR 2025, hear Dr. Dua & Dr. Boone discuss the latest data in GCA.
https://t.co/y4Bpk225Ia https://t.co/VWYE225dAv
Dr. John Cush RheumNow ( View Tweet)
The Rapidly Evolving Landscape of Cellular and Immune-based Therapies
When Henry Ford unveiled the Model T in 1908, the automobile industry was forever changed. A similar transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we https://t.co/RQuVETSTG4
Dr. John Cush RheumNow ( View Tweet)
💬 #ACR25 Topic Panels — LIVE!
Nov. 3 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 RA
Join Us Live on:
X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss these discussions https://t.co/i5UM0OBu86
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR25 - Day 1 Report
https://t.co/JayJCP9Rue https://t.co/B62mKbW4B8
Dr. John Cush RheumNow ( View Tweet)
"Personally I'm always ready to learn, although I do not always like being taught."
– Winston Churchill
Dr. John Cush RheumNow ( View Tweet)
Catching AxSpA Early: Closing the Diagnostic Gap
Dr. Akhil Sood reports on abstract 2635 and abstract 2636 presented at #ACR25.
https://t.co/TmJQKQUu9E https://t.co/6dWf8DY2W3
Dr. John Cush RheumNow ( View Tweet)
RA: Inject the Steroids
Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the #ACR25. https://t.co/xFQMIpi75S
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Best Abstracts - Day 1
The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expect, but some of these are gems.
https://t.co/tYY5xGOEGU https://t.co/wpQbvEcH1f
Dr. John Cush RheumNow ( View Tweet)
New Gout Therapies Show Promise in Phase III Trials
At #ACR25, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices https://t.co/Ff16L2CHc0
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases At #ACR25, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. https://t.co/CPob0ppjv3
Dr. John Cush RheumNow ( View Tweet)
💬 #ACR2025 Topic Panels — LIVE!
Nov. 2 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 PsA
Join Us Live on:
X Live • Facebook Live • YouTube Live • LinkedIn Live • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss https://t.co/A4pUjZG3Dr
Links:
Dr. John Cush RheumNow ( View Tweet)
Upadacitinib is a Double Edged Vascular Sword in GCA
Dr. David Liew discusses abstracts O751, O738, and O734 presented at #ACR25.
https://t.co/eTmVehP2Cd https://t.co/vxehwRWM2D
Dr. John Cush RheumNow ( View Tweet)
Hospitalization in Stills: Is it "Still" an infection?
Dr. Janet Pope discusses abstract 0163, "Trends in hospitalization and outcomes among patients admitted with Adult-onset Still’s disease in the United States: INSIGHTS FROM THE NATIONAL INPATIENT SAMPLE (2016-2022)," https://t.co/3Z0U9XN3nx
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid arthritis and the ‘big bang’ at #ACR25!
Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?
https://t.co/QDvdiP3q9R https://t.co/cz4j4vZkSd
Dr. John Cush RheumNow ( View Tweet)
SLE Conference Preview: progress in biologics at #ACR25
We now have four licensed targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis and belimumab and anifrolumab for active non-renal SLE). What are other issues to be addressed and https://t.co/uvVICAsCzo
Dr. John Cush RheumNow ( View Tweet)
AI Scribes Found their Favorite Doctors
Dr. Aurelie Najm discusses abstract 0189, "“Try it, you’ll love it”: Patterns of AI Scribes Use Among Rheumatologists", presented at #ACR25
https://t.co/QTYFvLa95Y https://t.co/ZIvMovloBL
Dr. John Cush RheumNow ( View Tweet)
